ELVN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
37.2M
+33.7%
27.8M
-18.8%
34.3M
+36.6%
25.1M
-12.2%
28.6M
R&D
29.0M
+40.2%
20.7M
-2.6%
21.2M
+16.6%
18.2M
-15.2%
21.5M
SG&A
8.2M
+15.1%
7.1M
-45.3%
13.0M
+89.8%
6.9M
-3.1%
7.1M
Operating Income
-37209000
-33.7%
-27823000
+18.8%
-34285000
-36.6%
-25096000
+12.2%
-28584000
EBITDA
-37202000
-33.8%
-27809000
+18.8%
-34239000
-36.8%
-25034000
+12.2%
-28503000
Net Income
-32485000
-37.5%
-23627000
+20.4%
-29667000
-47.2%
-20148000
+20.5%
-25335000
EPS (Basic)
$-0.49
-28.9%
$-0.38
+20.8%
$-0.48
-50.0%
$-0.32
+34.7%
$-0.49
EPS (Diluted)
$-0.49
-28.9%
$-0.38
+20.8%
$-0.48
-50.0%
$-0.32
+34.7%
$-0.49
Shares (Diluted)
66.2M
+5.4%
62.8M
+0.6%
62.4M
+0.5%
62.1M
+19.2%
52.1M
Enliven Therapeutics (ELVN) โ€” Financials